Q-omics provides the consensus-scored GALNT4 profile across patient tissues and cancer cell-line models. GALNT4 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GALNT4 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, GALNT4 RNA expression shows 20,427 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where GALNT4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GALNT4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GALNT4 survival associations across molecular data types. GALNT4 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GALNT4 RNA expression–survival associations across cancer types. High GALNT4 expression shows unfavorable associations in LGG and LUAD, but favorable associations in KIRC, UCEC, BRCA and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GALNT4 RNA expression.
This table summarizes GALNT4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GALNT4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GALNT4 shows lower tumor expression in THCA and higher tumor expression in LUAD, CHOL, LUSC, STAD and PAAD. The THCA box plot shows higher GALNT4 RNA expression in normal versus tumor tissue (log2 FC = −0.237, t-test p < 0.001).
This table shows molecular features associated with GALNT4 in patient tissues and cancer cell lines. In patient samples, GALNT4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GALNT4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
